ExoToe, founded in 2018 and headquartered in Johnston, Iowa, specializes in developing innovative hammertoe correction systems. The company's core mission is to provide effective, easy-to-use solutions for foot deformities, specifically targeting fractures and osteotomy. ExoToe offers a stainless steel fixation device that is simple to place, adjust, and remove, ensuring an appropriate angle of fusion. Their unique extramedullary device is only 0.6 mm thin, offering a less invasive and more efficient alternative to traditional methods.

Notable affiliated individuals and investors have not been disclosed. However, ExoToe has achieved significant milestones by introducing the first extramedullary device of its kind for hammertoe correction. This breakthrough has had a considerable impact on the market by providing a simpler, faster, and more cost-effective solution compared to existing options. The company's innovative approach has positioned it as a key player in the medical device industry, particularly in the niche of foot deformity correction.